Citius Pharmaceuticals Inc
CTXR
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.32M
Close$
$0.22
62.6% downside
Current Fair Value
62.6% downsideOvervalued by 62.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.32 Million |
|---|---|
| Enterprise Value | $3.54 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.38 |
| Beta | 1.05 |
| Outstanding Shares | 22,376,427 |
Return
| Return on Equity | -88.16% |
|---|---|
| Return on Assets | -40.93% |
| Return on Invested Capital | -73.84% |
Valuation & Multiples
| P/E Ratio | -0.32 |
|---|---|
| PEG | -0.22 |
| Price to Sales | - |
| Price to Book Ratio | 0.2 |
| Enterprise Value to Revenue | 0.63 |
| Enterprise Value to EBIT | -0.06 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.23 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$10.23 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
$5.46 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 53,000▼ 60.80% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.64%▼ 3.37% |
|---|---|
| Total Invested | $895,989▼ 32.98% |
| Investors Holding | 39▼ 2.00% |
ESG Score
No data
About Citius Pharmaceuticals Inc
10 employees
CEO: Myron Holubiak